Outcome of Board meeting held on July 28, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bharat Parenterals Ltd reported Q1FY26 results on July 28, 2025. Standalone revenue from operations rose modestly 2.5% YoY to ₹94.37 crore, while EBITDA was ₹15.41 crore with a margin of 16.32% (vs 16.29% YoY). Standalone PAT stood at ₹10 crore vs ₹12.18 crore in Q1FY25. On a consolidated basis, revenue grew strongly 25.4% YoY to ₹116 crore, driven by subsidiaries. Consolidated EBITDA jumped to ₹13.78 crore with margin expanding to 11.88% from 4.85% YoY, and the consolidated net loss narrowed sharply to ₹87 lakhs from ₹8.84 crore in Q1FY25. The Board also fixed the 32nd AGM for September 26, 2025, accepted the resignation of Mr. Sanjay Shah, appointed Mr. Alkesh Shah as Additional Director, re-appointed Mr. Mukeshbhai Patel as Independent Director, and appointed M/s Shah Mehta & Bakshi as new statutory auditors for a 5-year term.
Strong consolidated turnaround with revenue growth above 20% and significant EBITDA margin expansion signals improving subsidiary performance, though consolidated bottomline remains in losses. New statutory auditor appointment and director changes are routine governance items with no immediate material impact on shareholders.